Qiagen N V's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Qiagen N V (QGEN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Qiagen N V vs Its Competitors
- TTM: Trailing 12-month revenue of 2,034M vs 66,491M combined for its competitors (3.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+2.3%) for its tracked peer group.
- Growth: Qiagen N V generated 6.0% revenue growth year over year in Q4 2025, vs 7.3% for its competitors combined.
- Profitability: Its 20.9% net margin compares with 18.6% for the peer group.
- Scale: Qiagen N V ranks #13 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 1.1% of industry market cap.
- Peer revenue share: Qiagen N V accounted for 10.7% of combined revenue among its tracked peer group, down from 10.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.36M compares with $0.41M for the peer group (0.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
QGEN Sales vs. its Competitors, Q4 2025
Qiagen N V reported revenue growth of 6.00 % year on year in Q4 2025, below its competitors' combined revenue growth of 7.26 %.
With a net margin of 20.88 %, Qiagen N V achieved higher profitability than its competitors (18.63 %).
Qiagen N V generated 10.68 % of the combined sales of its peer group, down from 10.80 % a year earlier.
API endpoints for this dataset
Qiagen N V vs. its Competitors, Q4 2025
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Qiagen N V reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Qiagen N V and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Qiagen N v | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Qiagen N V's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.8% year over year, combined, vs 6.0% for Qiagen N V. Qiagen N V's share of combined industry revenue moved from 5.15% to 4.52%, a loss of 0.63 percentage points.
Qiagen N V's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Qiagen N v | Yes | Yes | No | No |
| Competitors combined (16) | ||||
| High-Confidence Competitors (8) | ||||
| Similar-Size Competitors (9) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 50.00 % (4 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
QGEN Stock Performance relative to its Competitors
QGEN Stock Performance relative to High-Confidence Competitors
QGEN Stock Performance relative to Similar-Size Competitors
QGEN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Twist Bioscience Corporation | 282.9% | Outperformed |
| 2 | Maravai Lifesciences Holdings Inc | 282.9% | Outperformed |
| 3 | Illumina Inc | 282.9% | Outperformed |
| 4 | Guardant Health Inc | 282.9% | Outperformed |
| 5 | Pacific Biosciences Of California Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Qiagen N V's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Qiagen N v
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Qiagen N v |
11,016.23 | 2,034.50 |
 Thermo Fisher Scientific Inc |
257,755.96 | 47,351.00 |
 Agilent Technologies inc |
49,457.08 | 7,372.00 |
 Illumina Inc |
32,822.02 | 4,538.00 |
 Guardant Health Inc |
20,045.64 | 1,183.11 |
 Bio techne Corp |
11,427.12 | 1,213.87 |
| SUBTOTAL | 415,124.64 | 68,537.41 |
Sign in to see all competitors of Qiagen N v .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Qiagen N v versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Qiagen N V's Competitors Named by the Company
Competitive relationships identified from Qiagen N V reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Guardant Health Inc | Company report | 85% |
| Quidelortho Corp | Company report | 85% |
| Guided Therapeutics Inc | Company report | 85% |
| Volitionrx Limited | Company report | 85% |
| Virax Biolabs Group Limited | Company report | 85% |
| Co diagnostics Inc | Company report | 85% |
| Caredx Inc | Company report | 85% |
| OPGN | Company report | 85% |
| Capforce Inc | Company report | 85% |
| Veracyte Inc | Company report | 85% |
| Cue Health Inc | Company report | 85% |
| Bio techne Corp | Company report | 85% |
| Illumina Inc | Company report | 85% |
| Standard Biotools Inc | Company report | 85% |
| Repligen Corp | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Maravai Lifesciences Holdings Inc | Company report | 85% |
| Pacific Biosciences Of California Inc | Company report | 85% |
| Nanostring Technologies Inc | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
| Olink Holding Ab publ | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Qiagen N V's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Qiagen N V's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Thermo Fisher Scientific Inc | Clinical Research 20.15 % |
| Agilent Technologies inc | Agilent CrossLab 41.36 % |
| Illumina Inc | Sequencing 90.43 % |
| Guardant Health Inc | Reportable 100.00 % |
| Bio techne Corp | Protein Sciences 73.30 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Qiagen N V's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Qiagen N v | 11,016 | 356,929 | 74,540 |
| Thermo Fisher Scientific Inc | 257,756 | 378,808 | 56,712 |
| Agilent Technologies inc | 49,457 | 407,293 | 79,558 |
| Illumina Inc | 32,822 | 3,545,313 | 699,219 |
| Guardant Health Inc | 20,046 | 472,109 | -180,940 |
| Bio techne Corp | 11,427 | 404,623 | 60,621 |
| PEERS TOTAL | 404,108 | 409,357 | 56,304 |
Qiagen N V's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Qiagen N v | United States 49.08 % |
| Thermo Fisher Scientific Inc | North America 51.63 % |
| Agilent Technologies inc | Americas 41.63 % |
| Illumina Inc | United States and Canada 56.42 % |
| Guardant Health Inc | United States 95.67 % |
| Bio techne Corp | US 50.94 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Qiagen N V's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Qiagen N V's industry classification, broader than the peer set above. Market cap in millions of $.Qiagen N V ranks #13 of 158 companies by market capitalization in its industry, holding 1.14 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,353, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 250,468 | 26.02 % |
| 2 | Gilead Sciences Inc | 207,444 | 21.55 % |
| 3 | Moderna Inc | 101,168 | 10.51 % |
| 4 | Argenx Se | 61,223 | 6.36 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 13 | Qiagen N v | 11,016 | 1.14 % |
Market cap and industry share for the rest of Qiagen N V's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Qiagen N V's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 8 | Mesoblast Limited | 18,438 | -10.36 % |
| 9 | Exelixis Inc | 18,066 | 69.46 % |
| 10 | Neurocrine Biosciences Inc | 17,154 | 3.81 % |
| 11 | Kymera Therapeutics Inc | 12,933 | 109.07 % |
| 12 | Halozyme Therapeutics Inc | 1,234 | 12.3% |
| 13 | Qiagen N v | 11,016 | 14.55 % |
| 14 | Repligen Corp | 1,234 | 12.3% |
| 15 | Vaxcyte Inc | 1,234 | 12.3% |
| 16 | Krystal Biotech Inc | 1,234 | 12.3% |
| 17 | Immunitybio inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Qiagen N V's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Qiagen N V's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (160 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 63.87 % | 34.84 % (avg) | +29.0 pp |
| Operating Margin | 22.90 % | industry median | +16.4 pp |
| EBITDA Margin | 27.45 % | -2.62 % (avg) | +30.1 pp |
| Capital Intensity (Capex / Revenue) | 0.30 % | 8.89 % (avg) | -8.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Qiagen N V's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 23.8x | 27.3x | -3.5x |
| EV / EBITDA | 16.7x | 17.0x | -0.3x |
| P/B | 2.7x | 5.1x | -2.4x |
| Return on Equity | 11.25 % | industry aggregate | 0.88 % |
| Return on Invested Capital | 6.01 % | -11.80 % (avg) | 17.81 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Qiagen N V's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -8.67 % | 0.98 % | 6.00 % |
| Operating Margin | 21.57 % | 5.09 % | 22.90 % |
| Return on Invested Capital | 4.39 % | 1.13 % | 6.01 % |
| P/E | 28.0x | 117.7x | 23.8x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Qiagen N V's Strategic Group Map
Qiagen N V is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Qiagen N V's trailing-12-month revenue growth of 6.0% and operating margin of 22.9% compares with an average of 10.1% growth and 22.2% margin across its 8 closest peers by combined growth, margin and ROIC -- Qiagen N V sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Qiagen N V's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Qiagen N V falls in the Dog quadrant: relative market share of 0.04x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Qiagen N V's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,353 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.30 % vs industry average 8.89 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Qiagen N V's dedicated Suppliers and Customers pages, not here.
Qiagen N V's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Qiagen N V falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Qiagen N V's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 16.4 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.04x).
Opportunities
- Trades at a lower P/E than the industry average (23.8x vs 27.3x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Qiagen N V's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Qiagen N v | 1.53 | 3.90 | - |
| Thermo Fisher Scientific Inc | 0.39 | 1.69 | 0.81 |
| Agilent Technologies inc | 0.77 | 2.02 | 1.02 |
| Illumina Inc | - | 2.02 | 0.68 |
| Guardant Health Inc | 2.56 | 4.29 | - |
| Bio techne Corp | 1.23 | 4.16 | 0.13 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Qiagen N V's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Qiagen N v | Q4 2025 | +6.0 % | +408.3 % |
| Thermo Fisher Scientific Inc | Q3 2026 | +9.1 % | +6.2 % |
| Agilent Technologies inc | Q2 2026 | +8.1 % | +7.7 % |
| Illumina Inc | Q3 2026 | +4.2 % | +46.7 % |
| Guardant Health Inc | Q2 2026 | +44.3 % | - |
| Bio techne Corp | Q2 2026 | +1.1 % | - |
| PEERS TOTAL | +8.5 % | +29.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Qiagen N V's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Qiagen N v | Q4 2025 | -22.8 % | +49.4 % |
| Thermo Fisher Scientific Inc | Q3 2026 | +133.0 % | +8.2 % |
| Agilent Technologies inc | Q2 2026 | -1.6 % | -22.3 % |
| Illumina Inc | Q3 2026 | -14.8 % | +29.0 % |
| Guardant Health Inc | Q2 2026 | +42.8 % | +108.2 % |
| Bio techne Corp | Q2 2026 | -7.7 % | +73.4 % |
Qiagen N V's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Qiagen N v | 6.76% | 10.69% | 11.25% |
| Thermo Fisher Scientific Inc | 6.29% | 7.46% | 13.32% |
| Agilent Technologies inc | 10.97% | 19.84% | 41.99% |
| Illumina Inc | 13.43% | 18.74% | 31.45% |
| Guardant Health Inc | - | - | - |
| Bio techne Corp | 7.12% | 7.61% | 9.01% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Qiagen N V's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Qiagen N v | 25.94 | 5.41 |
| Thermo Fisher Scientific Inc | 36.72 | 5.44 |
| Agilent Technologies inc | 34.47 | 6.71 |
| Illumina Inc | 36.81 | 7.23 |
| Guardant Health Inc | - | 16.94 |
| Bio techne Corp | 63.29 | 9.41 |
| PEERS AVERAGE | 43.37 | 6.06 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.